198 related articles for article (PubMed ID: 14710894)
1. Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2.
Rook AH; Kuzel TM; Olsen EA
Hematol Oncol Clin North Am; 2003 Dec; 17(6):1435-48, ix. PubMed ID: 14710894
[TBL] [Abstract][Full Text] [Related]
2. Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma.
Rook AH; Junkins-Hopkins JM; McGinnis KS; Wysocka M; Richardson SK; Budgin JB; Everitts S; Vittorio CC
Adv Dermatol; 2002; 18():29-43. PubMed ID: 12528401
[TBL] [Abstract][Full Text] [Related]
3. The role for interleukin-12 therapy of cutaneous T cell lymphoma.
Rook AH; Zaki MH; Wysocka M; Wood GS; Duvic M; Showe LC; Foss F; Shapiro M; Kuzel TM; Olsen EA; Vonderheid EC; Laliberte R; Sherman ML
Ann N Y Acad Sci; 2001 Sep; 941():177-84. PubMed ID: 11594571
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous T-cell lymphoma. New immunomodulators.
Apisarnthanarax N; Duvic M
Dermatol Clin; 2001 Oct; 19(4):737-48. PubMed ID: 11705358
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory effects of rexinoids.
Foss F
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S21-5. PubMed ID: 16516672
[TBL] [Abstract][Full Text] [Related]
6. Denileukin diftitox.
Saxon M
Clin J Oncol Nurs; 2000; 4(6):289, 293. PubMed ID: 11899329
[TBL] [Abstract][Full Text] [Related]
7. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches.
Weiner DM; Durgin JS; Wysocka M; Rook AH
J Am Acad Dermatol; 2021 Mar; 84(3):597-604. PubMed ID: 33352268
[TBL] [Abstract][Full Text] [Related]
8. [Novel treatment modalities in cutaneous T cell lymphoma. Biologic response modifiers].
Marschalkó M
Orv Hetil; 2005 Jun; 146(23):1251-5. PubMed ID: 15988920
[TBL] [Abstract][Full Text] [Related]
9. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
10. Management of cutaneous T-cell lymphomas: Established and emergent therapies.
Wain T; Venning VL; Consuegra G; Fernandez-Peñas P; Wells J
Australas J Dermatol; 2019 Aug; 60(3):200-208. PubMed ID: 30809800
[TBL] [Abstract][Full Text] [Related]
11. Choices in the treatment of cutaneous T-cell lymphoma.
Hymes KB
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):18-23. PubMed ID: 17474355
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL.
Kadin ME; Vonderheid EC
Nat Rev Clin Oncol; 2010 Aug; 7(8):430-2. PubMed ID: 20668480
[No Abstract] [Full Text] [Related]
13. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
[TBL] [Abstract][Full Text] [Related]
14. Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma.
Richardson SK; McGinnis KS; Shapiro M; Lehrer MS; Kim EJ; Vittorio CC; Junkins Hopkins JM; Rook AH
J Cutan Med Surg; 2003; 7(4 Suppl):8-12. PubMed ID: 12958701
[No Abstract] [Full Text] [Related]
15. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
Duvic M
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
[TBL] [Abstract][Full Text] [Related]
16. Interleukins in the treatment of mycosis fungoides.
Gerami P; Guitart J; Rosen S; Kuzel TM
G Ital Dermatol Venereol; 2008 Feb; 143(1):55-8. PubMed ID: 18833051
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous T-cell lymphoma: Biologic targets for therapy.
Choi J; Foss F
Curr Hematol Malig Rep; 2007 Oct; 2(4):272-7. PubMed ID: 20425380
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic advances in biological response modifiers in the treatment of cutaneous T-cell lymphoma.
Vittorio CC; Rook AH; French LE; Shapiro M; Lehrer MS; Junkins-Hopkins JM
BioDrugs; 2001; 15(7):431-7. PubMed ID: 11520254
[TBL] [Abstract][Full Text] [Related]
19. Systemic therapy of cutaneous T-cell lymphoma (CTCL).
Alpdogan O; Kartan S; Johnson W; Sokol K; Porcu P
Chin Clin Oncol; 2019 Feb; 8(1):10. PubMed ID: 30818958
[TBL] [Abstract][Full Text] [Related]
20. Management of refractory early-stage cutaneous T-cell lymphoma.
Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
